The Janus of lupus - benefits and risks with B-cell therapy

被引:1
作者
van Vollenhoven, R. F. [1 ]
机构
[1] Karolinska Inst, Rheumatol Unit, Stockholm, Sweden
关键词
D O I
10.1177/0961203308090033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Janus was the Roman god of doorways and beginnings. Thus, if B-cell directed therapy is indeed the beginning of a new era in SLE therapy, his would be an appropriate face to regard in this context. But there is a problem: he is a two-faced god. Janus faces in two different directions: past and future, youth and adulthood, barbarism and civility. With respect to biological treatments, perhaps Janus' faces are the efficacy and the safety dimensions of therapy. In this review, I will consider Janus' second face, the safety side of B-cell therapy. I will argue that, while safety data have been rather reassuring so far, vigilance is required; and I will point out three specific mistaken assumptions regarding the safety of B-cell directed therapy in SLE.
引用
收藏
页码:447 / 449
页数:3
相关论文
共 24 条
[1]   The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].
Anolik, JH ;
Campbell, D ;
Felgar, RE ;
Young, F ;
Sanz, I ;
Rosenblatt, J ;
Looney, RJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459
[2]  
[Anonymous], 2007, FDA Consum, V41, P3
[3]   Progressive multifocal leukoencephalopathy and natalizumab - Unforeseen consequences [J].
Berger, JR ;
Koralnik, IJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) :414-416
[4]   Progressive multifocal leukoencephalopathy in rheumatic diseases - Evolving clinical and pathologic patterns of disease [J].
Calabrese, Leonard H. ;
Molloy, Eamonn S. ;
Huang, DeRen ;
Ransohoff, Richard M. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (07) :2116-2128
[5]  
COIFFIER B, 2007, BLOOD 1114
[6]   Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus [J].
Dall'Era, Maria ;
Chakravarty, Eliza ;
Wallace, Daniel ;
Genovese, Mark ;
Weisman, Michael ;
Kavanaugh, Arthur ;
Kalunian, Kenneth ;
Dhar, Patricia ;
Vincent, Emmanuelle ;
Pena-Rossi, Claudia ;
Wofsy, David ;
Serono, Merck .
ARTHRITIS AND RHEUMATISM, 2007, 56 (12) :4142-4150
[7]  
Ding CH, 2006, CURR OPIN INVEST DR, V7, P464
[8]   Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab [J].
Gelinck, L. B. S. ;
Teng, Y. K. O. ;
Rimmelzwaan, G. F. ;
van den Bemt, B. J. F. ;
Kroon, F. P. ;
van Laar, J. M. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (10) :1402-1403
[9]   Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis [J].
Gunnarsson, Iva ;
Sundelin, Birgitta ;
Jonsdottir, Thorunn ;
Jacobson, Stefan H. ;
Henriksson, Elisabet Welin ;
van Vollenhoven, Ronald F. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (04) :1263-1272
[10]   Rituximab-induced long-term remission of membranous lupus nephritis [J].
Jacobson, Stefan H. ;
van Vollenhoven, Ronald ;
Gunnarsson, Iva .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (06) :1742-1743